The Leukemia Patient Advocates Foundation (LePAF) is a patient-led, charitable non-profit foundation registered in Switzerland. Its mission is to improve the lives and survival of patients affected by leukemia and other hematological malignancies.
In order to improve the life and survival rates of leukemia patients worldwide and in order to support their relatives, the foundation offers an international platform for the education of and the exchange between patients advocates as well as their organisations.
The foundation cooperates with the most influential players that deal with the research and therapy of hematological cancers as well as healthcare policy and patient advocacy.
The foundation acts as a legal entity for four self-sustained patient advocacy networks:
- CML Advocates Network (CMLAN)
- MPN Advocates Network (MPNAN)
- CLL Advocates Network (CLLAN)
- Acute Leukemia Advocates Network (ALAN)
VISION AND MISSION
Our vision is a world in which all leukemia patients have access to the best treatment, care and support available.
Our mission is:
To improve the lives and survival rates of patients affected by leukemia, as well as their relatives, worldwide
To support patient advocates in providing help and support to leukemia patients and their relatives
To provide a platform for education and best practice sharing of leukemia patient groups and their representatives worldwide
To collaborate with other stakeholders involved in research, treatment and care of patients with hematological cancers
The foundation’s board supervises the foundation, its activities and finances, establishes legal representatives and committees, and represents the foundation towards the public and Swiss authorities.
The four self-sustained patient advocacy networks are formally committees of the Foundation. At least one trustee of the foundation board must be part of every committee in order to assure compliance with the purpose of the foundation, having a veto right on all committee decisions that may contradict the foundation’s rules, its financial viability or applicable laws and regulations.
The Leukemia Patient Advocates Foundation´s board is currently composed of the following trustees:
- Jana Pelouchová (President, Czech Republic)
- Jan Geißler (Vice President and Managing Director, Germany)
- Giora Sharf (Treasurer, Israel)
- Erik Aerts (Board Member, Switzerland)
CML Advocates Network
The global CML Advocates Network (CMLAN) connects patient organisations in more than 90 countries on all continents. It was founded by four CML patient leaders from Germany, Israel, Czech Republic and UK and is led by a Steering Committee of nine CML patient advocates from all six world regions.
MPN Advocates Network
The global MPN Advocates Network (MPNAN) was founded by representatives from the Netherlands, Spain and the UK. The MPN Advocates Network’s immediate goal is to increase the international scope of the organisation by contacting MPN patient groups in other countries and inviting them to become part of the network. The initial focus will be groups in Europe, but the intention is to be a worldwide organisation.
CLL Advocates Network
The CLL Advocates Network (CLLAN) is the global network of chronic lymphocytic leukaemia (CLL) patient groups. It was founded in 2014 by representatives from Canada, Czech Republic, France, Ireland, Italy, Portugal, UK and the United States. As a global network, the CLL Advocates Network’s mission is to enhance CLL patient care and improve patients’ outcomes.
Acute Leukemia Advocates Network (ALAN)
The Acute Leukemia Advocates Network (ALAN) is an independent global network of patient organisations representatives and patient organisations in the area of acute leukemias.